Contact
Header_1077x260px_About_Profil.jpg

iPDM Goes Europe: tangible impact on diabetes patients and care

Treatment inertia calls for an integrated personalized diabetes management: iPDM

Diabetes represents a huge and multidimensional challenge for European societes. It not only leads to premature ageing and frailty but also promotes chronic conditions like cardiovascular disease, blindness, dementia and even cancer. Despite the availability of numerous treatment options treatment inertia is still a common problem: many patents still fail to reach their treatment goals. According to the UK National Diabetes Audit data 2016- 2017, only 30% of people with type 1 diabetes and 67% of people with type 2 diabetes achieved a HbA1c target of not more than 58 mmol/l (7.5%).

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Sep 3, 2019 5:17:00 PM
prof-dr-freimut-schliess

NAFLD/NASH: a ticking bomb not yet defused

Unmet medical needs in NAFLD and NASH

NAFLD (non-alcoholic fatty liver disease) comprises a spectrum of conditions starting with adiposity of the liver (fatty liver, steatosis hepatis) and ranging up to NASH (non-alcoholic steatohepatitis). Currently about 30% of the general population and 60-80% of people with type 2 diabetes are considered to be affected by NAFLD [1].

Premature mortality from NAFLD comes from the development of diabetes and cardiovascular disease and progression of the fatty liver to the more irreversible and aggressive NASH which again predisposes for incident liver cirrhosis and hepatocellular carcinoma [2]. Despite the potentially disastrous outcome of NAFLD and an increasingly rich knowledge concerning the underlying molecular pathogenesis no rational drugs and therapies specifically dedicated to the treatment of NAFLD are available yet. 

In this blog we first provide a brief overview on the key pathogenetic drivers in NAFLD. Then we highlight the inherent opportunities and challenges for developers of lifestyle interventions and drugs tackling NAFLD. And last but not least we discuss some key issues related to the design and implementation of clinical trials in NAFLD and NASH.

If you want to learn more on Profil’s general perception of the liver’s role in health and disease you are invited to read our „Liver first? The liver in diabetes and cardiovascular disease“ series of blogs (part I, part II, part III).

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Apr 25, 2019 5:25:00 PM
prof-dr-freimut-schliess

Profil joined iPDM-GO

Personalized Diabetes Management in Europe

In the year 2018 Profil joined the team creating the iPDM-GO (integrated Personalized Diabetes Management Goes Europe) consortium for implementing integrated Personalized Diabetes Management in Europe. Following a thorough and competitive evaluation the iPDM-GO project at the beginning of 2019 became part of the Innovation portfolio curated by EIT Health. EIT Health is a public-private knowledge and innovation community (KIC) of best-in-class health innovators backed by the European Union. The KICs Innovation ecosystem enables a collaborative multi-stakeholder approach to implementing a more effective diabetes management in Europe.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Apr 16, 2019 5:07:00 PM
prof-dr-freimut-schliess

Artificial pancreas in type 2 diabetes

Close the loop in diabetes care

Artificial pancreas systems are medical products that use algorithms informed by continuous glucose monitoring (CGM) data of a given patient, thereby regulating the rates of a continuous subcutaneous insulin infusion through an insulin pump. In this way, artificial pancreas systems are taking over control of the patient’s blood glucose levels.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Feb 19, 2019 5:21:00 PM
prof-dr-freimut-schliess

Digital Diabetes: better trials, better drugs, better care

Background

Diabetes is a multidimensional challenge for global societies. Despite the availability of drugs and technology many patients don’t reach their treatment goals.  According to the UK National Diabetes Audit data 2016-2017 only 30% of people with type 1 diabetes and 67% of people with type 2 diabetes achieved a HbA1c target of 58 mmol/l (7.5%). When considering also blood pressure and cholesterol targets, these figures dropped to 19% and 41% respectively.

The good news is that diabetes leaves a huge room for Innovation. Risk factors are modifyable, type 2 diabetes is potentially reversible and the role of the patient’s self-management is of outstanding importance. Diabetes could serve as a paradigm for cracking down treatment inertia and narrowing the gap between the efficacy of investigational medicinal products seen in well controlled clinical trials and the lower than expected effectiveness of drugs observed in real-world chronic care (E2E gap) [1].

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Jan 29, 2019 5:13:00 PM
prof-dr-freimut-schliess

Profil explores opportunities for artificial pancreas in type 2 diabetes

Highlighting the role of open and trans-sectoral collaboration in the advancement of artificial pancreas solutions

Profil has recently published a peer-reviewed article on the topic of “Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project ” in the Journal of Diabetes Science and Technology. Profil is the organisation coordinating CLOSE. The article is authored by CLOSE industry and academic partners, representatives of the EIT Health public-private partnership management boards, and key opinion leaders in the field.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Oct 2, 2018 5:18:00 PM
prof-dr-freimut-schliess

Do-It-Yourself Artificial Pancreas systems (DIY APS)

The way forward to closed-loop metabolic control in diabetes care?

The challenge

Diabetes represents a huge and multidimensional challenge. Despite the availability of numerous treatment options, many patents still fail to reach their treatment goals. Administration of  the right amount of insulin at the right time still poses a great challenge for the self-management of many people with diabetes.

Accordingly there is a huge need to implement new innovative products and services improving both the effectiveness of diabetes care and the quality of life for people with diabetes. Particularly user-centered products and sercvices co-created with stakeholders including people with diabetes may have a high potential to increase treatment adherence thereby reducing the enormous pressure on healthcare systems.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Sep 5, 2018 5:16:00 PM
prof-dr-freimut-schliess

D4kids: Profil joined a new pan-European Artificial Pancreas initiative

Profil is part of the new Diabeloop for children (D4kids) pan-European consortium for functionally enhancing an Artificial Pancreas (AP) system to better serve the needs and requirements of children with type 1 diabetes (T1D) and their families.

Based on a co-creative approach and clinical evidence D4kids will adapt the AP system with the ambition to

  • ameliorate the long-term trajectories of T1D
  • enhance the quality of life of children and their families
  • boost pediatric care
  • improve the sustainability of European healthcare Systems
Read More

Topics: About Profil, Treating Diabetes

Posted by Prof. Dr. Freimut Schliess on May 2, 2018 4:53:00 PM
prof-dr-freimut-schliess

Artificial pancreas for type 2 diabetes: the CLOSE project

There is a great and ever increasing socioeconomic burden on Europe due to the prevalence of people with multiple chronic diseases. CLOSE (Automated glucose control at home for people with chronic disease) serves to innovate homecare for insulin treated patients with type 2 diabetes mellitus (T2DM) by offering an integrated product and service package (AP+). Blood glucose levels will be controlled by an artificial pancreas (AP) that will be installed at the patients' home, operated through trained caregivers, and remote controlled (telehealth).

Read More

Topics: Clinical Trials in Diabetes, Treating Diabetes

Posted by Prof. Dr. Freimut Schliess on Jan 18, 2018 5:03:00 PM
prof-dr-freimut-schliess

Glucose Clamps: 2 steps towards hepatic and peripheral insulin sensitivity

Context

The hyperinsulinemic euglycemic clamp is the gold standard required by regulatory authorities for quantifying the glucodynamics of insulin preparations in clinical trials. Glucose clamping avoids confounding effects due to fluctuations in blood glucose concentrations as seen in the insulin tolerance test.

The hyperinsulinemic euglycemic clamp is also the method of choice for measuring human insulin sensitivity in clinical trials (deFronzo et al., 1979; Heise & Heinemann, 2001; Heise et al., 2016). Today CE-labeled medical devices like ClampArt® are available. ClampArt® takes advantage from an intravenous (iv) continuous blood glucose monitoring and a smart algorithm.

Read More

Topics: The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Aug 9, 2017 5:00:00 PM
prof-dr-freimut-schliess

Subscribe to our monthly blog updates

Find out more: Glucose Clamp Webinar

Subscribe to Email Updates

Our most popular Posts